FDA 483 / Warning Letter

Receiving an FDA 483 or FDA Warning letter can be an alarming experience. Letters notify regulated industries about violations documented during FDA inspections or investigations, and typically pertain to products, practices, or processes, and can create alarm for recipients.

Compliance Insight can handle FDA 483 and Warning responses for industries across the life science market, including: medical devices, dietary supplements, drugs, clinical trials, and biologics. We also help prevent future 483 issuances by providing compliance training and administering mock inspections.

If you receive a 483 notice the letter will make clear when and how you must inform the FDA of your plan for correction. We urge you to seek assistance as soon as possible, so we can resolve your issue quickly and efficiently.

What is an FDA 483 Observation?

An FDA 483 is a written list of observations issued by an FDA investigator at the close of a facility inspection. It identifies conditions or practices that may constitute violations of the Food, Drug, and Cosmetic Act. Receiving a 483 is serious, but it is not a final enforcement action. It is your opportunity to respond before the situation escalates to a Warning Letter.

What is an FDA Warning Letter?

An FDA Warning Letter is a formal enforcement action issued when FDA determines that significant violations remain uncorrected after a 483 response or when no response was provided. Warning Letters are publicly posted on FDA’s website and can affect your business relationships, contracts, and reputation. Acting quickly and responding effectively is critical.

How Compliance Insight Can Help

Compliance Insight provides end-to-end FDA 483 and Warning Letter response consulting for companies across the life science market, including pharmaceutical manufacturers, medical device companies, dietary supplement producers, clinical trial organizations, and biologics firms. We can engage within 24 hours of contact.

Our services include: root cause analysis for each observation, CAPA plan development, drafting the formal written response to FDA, review of supporting documentation, and post-response follow-up support. We also help prevent future 483 issuances through compliance training and mock inspections.

Frequently Asked Questions

What is an FDA 483 observation?

An FDA 483 is a written list of observations issued by an FDA investigator at the close of an inspection. It identifies conditions or practices the investigator believes may violate the Food, Drug, and Cosmetic Act. It is not a final enforcement action.  It is an opportunity to address concerns before they escalate. Receiving a 483 does not mean your company has been found guilty of a violation, but it does require a prompt, well-structured written response.

How long do I have to respond to an FDA 483?

There is no statutory deadline for responding to an FDA 483, but FDA strongly expects a written response within 15 business days of receiving the form. A timely, detailed response demonstrates good faith and significantly reduces the risk of escalation to a Warning Letter. Compliance Insight can engage within 24 hours to help you meet this timeline.

What is the difference between an FDA 483 and a Warning Letter?

An FDA 483 is issued by the investigator who conducted your inspection and represents their personal observations. A Warning Letter is a formal enforcement action issued by an FDA Center after FDA leadership has determined that significant regulatory violations remain uncorrected. Warning Letters are publicly posted on FDA’s website and can affect business relationships, contracts, and investor confidence. The 483 response process is your best opportunity to prevent a Warning Letter from being issued.

What should an FDA 483 response include?

An effective FDA 483 response should address each observation individually and include: a root cause analysis explaining why the issue occurred, a description of immediate corrective actions already completed, a CAPA plan with specific steps and target completion dates, and any supporting documentation such as updated SOPs or training records. FDA evaluates the quality of your response — vague or incomplete answers are as concerning as no response at all.